akash.verma@cenmed.com
(732) 447-1115
InformationRBN-2397 RBN-2397 is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. RBN-2397 has the potential for the research of tumor treatment.TargetsPARP7 (Cell-free assay); PARP7 (Cell-free assay) <0.001 μM(Kd); <3 nMIn vitroRBN-2397 restores cytosolic nucleic acid sensing and blocks cell proliferation in a human lung cancer cell line.In vivoRBN-2397 causes complete regressions in human NSCLC NCI-H1373 xenografts and dose-dependent pharmacodynamic effects. RBN-2397 induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses.Cell Research(from reference)Cell lines：NCI-H1373 human lung cancer cells Concentrations：0.4 nM to 1000 nM Incubation Time：24 h
Specifictaions: ≥99%
MDL Number: C20H23F6N7O3
Molecular Formula: 523.43
PubChem CID: 146047148
Isomeric SMILES: C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/R414312-SCI_511d663daaed2b68fce97cfbb69134ef.pdf
- UPC:
- 12141805
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- R414312-1mg
- CAS:
- 2381037-82-5
- Product Size:
- 1mg
- Hazard Statement Codes:
- H302
- Precautionary Statement Codes:
- P305+P351+P338
